Nanoscope Therapeutics Executives to Speak at Advanced Therapies USA 2026

Nanoscope Therapeutics announced that members of its leadership team are scheduled to participate in the Advanced Therapies USA 2026 conference, taking place November 4–5, 2026, at the Hynes Convention Center in Boston, Massachusetts. The company stated that sessions will address scientific, regulatory, commercial, and market access pathways for its investigational product, MOGENRY (sonpiretigene isteparvovec; MCO-010), which is currently under review by the U.S. Food and Drug Administration (FDA) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA).

Leadership Participation and Scheduled Sessions

According to the company's announcement, several executives will present or join panel discussions during the event:

• Sulagna Bhattacharya (Co-Founder and CEO) is scheduled to join a keynote panel discussion on navigating the cell and gene therapy landscape on Wednesday, November 4, 2026.
• Samarendra Mohanty (Co-Founder, President, and Chief Scientific Officer) is scheduled to present on disease-agnostic gene therapy for neurodegenerative conditions and participate in a keynote panel on investment in advanced therapies on Thursday, November 5, 2026.
• Ramesh Arjunji (Executive Vice President, Value & Access) is scheduled to present on building early evidence for rare disease access and pricing, and join a panel on expanding access to cell and gene therapies on November 4, 2026.
• Ananta Ayyagari (Senior Director of Regulatory Affairs) is scheduled to present on navigating global regulatory filings on November 5, 2026.

About MOGENRY (MCO-010)

MOGENRY is an investigational, one-time, in-office, intravitreal optogenetic gene therapy utilizing Nanoscope's multi-characteristic opsin (MCO) platform. The therapy is designed to deliver a synthetic opsin gene to surviving bipolar retinal cells, making them directly light-sensitive following photoreceptor loss.

The company reported that MOGENRY is currently under FDA review for the treatment of retinitis pigmentosa (RP) with severe vision loss, and under priority review by the PMDA and MHLW in Japan for inherited retinal dystrophies (IRDs). Additionally, Nanoscope noted ongoing clinical evaluations in Stargardt disease and preparations for future programs, such as geographic atrophy.

Practical Implications and Verification

Industry stakeholders, investors, and potential partners attending the conference can meet with Nanoscope leadership during the scheduled dates in Boston. Interested parties can verify the conference schedule and official announcements through the official Nanoscope Therapeutics website or the Advanced Therapies USA 2026 event portal.